CytomX Therapeutics (6C1) Price & Analysis
6C1 Stock Chart & Stats
- Day’s Range
- EUR 2.00 - EUR 2.00
- 52-Week Range
- EUR 1.96 - EUR 6.97
- Previous Close
- EUR 2.09
- Volume
- 0
- Average Volume (3M)
- 27
- Market Cap
- EUR 455.02M
- Enterprise Value
- EUR 495.53M
- Total Cash (Recent Filing)
- EUR 330.28M
- Total Debt (Recent Filing)
- EUR 5.70M
- Price to Earnings (P/E)
- ―
- Beta
- 1.44
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- -0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Balance-Sheet Leverage
Minimal debt reduces near-term balance-sheet strain and interest-related pressure while preserving flexibility to fund clinical programs. The improved equity base and asset position also provide a stronger capitalization foundation than earlier periods with negative equity.
High Gross Profitability
Very high gross profitability indicates that partnered and licensing revenue can carry attractive economics when payments are received. If CytomX advances additional programs or expands collaborations, this structure may support strong incremental margins despite clinical-stage operating costs.
Probody Oncology Platform
CytomX is built around a differentiated platform approach intended to improve the therapeutic window of cancer treatments. A reusable discovery technology can support multiple proprietary and partnered candidates, creating potential for recurring development opportunities across oncology.
Bears Say
Sharp Revenue Contraction
Revenue is declining sharply and remains volatile, showing that CytomX lacks a stable, recurring commercial revenue base. This makes operating performance highly dependent on the timing and success of collaboration, licensing, and development-related payments.
Substantial Cash Burn
Large ongoing cash usage means the company is not self-funding its operations and must rely on existing reserves or external capital. Continued clinical development therefore carries financing pressure, potentially limiting program flexibility if cash needs remain elevated.
Persistent Losses
Sustained losses demonstrate that current collaboration and development activity does not yet cover the company’s operating base. Negative returns can erode capital over time and increase dependence on successful milestones, partnerships, or future financing to support growth.
CytomX Therapeutics News
6C1 FAQ
What was CytomX Therapeutics’s price range in the past 12 months?
What is CytomX Therapeutics’s market cap?
When is CytomX Therapeutics’s upcoming earnings report date?
How were CytomX Therapeutics’s earnings last quarter?
Is CytomX Therapeutics overvalued?
Does CytomX Therapeutics pay dividends?
What is CytomX Therapeutics’s EPS estimate?
How many shares outstanding does CytomX Therapeutics have?
What happened to CytomX Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CytomX Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
CytomX Therapeutics Stock Smart Score
Company Description
CytomX Therapeutics
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sean A. McCarthy
- Employees
- 69
- Website
- www.cytomx.com
- Address
- 151 Oyster Point Boulevard, South San Francisco, CA, 94080, US
CytomX Therapeutics (6C1) Earnings & Revenues
6C1 Earnings Call
Earnings Call SentimentPositive
The call emphasized substantial clinical progress and clear near-term development and regulatory plans for Varseta-M (robust ORR 20%–32% and ~7 months PFS, completed optimization enrollment, combination and expansion strategies), backed by a materially strengthened balance sheet (cash up ~152.9%) and runway into H2 2028. Key risks remain operational and clinical: a large year-over-year revenue decline driven by completed collaborations, modest increases in operating costs, and the need to confirm that Grade 3 diarrhea can be reliably managed in the full optimization cohort and over longer follow-up. Overall, the positive clinical momentum and strong cash position outweigh the near-term financial and clinical uncertainties.
View all DE:6C1 earnings summaries6C1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 6 | 11 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 4 | 0 | 8 |